Computational modeling in drug disposition

42,939 views 21 slides Feb 06, 2019
Slide 1
Slide 1 of 21
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21

About This Presentation

Computational modeling in drug disposition


Slide Content

Computational Modeling in Drug Disposition Himal Barakoti M.pharm , 2 nd sem Faculty of Pharmaceutical science Assam Down Town University

Contents Introduction Modeling Technique Drug Absorption ( Solubility and Intestinal Permeation) Drug Distribution Drug Excretion Active Transport ( P- gp , BCRP, Nucleoside Transporters, hPEPT1, ASBT, OCT, OACP , BBB-Choline Transporter) Current Challenges and future Directions Faculty of Pharmaceutical science, ADTU 2

Introduction Historically , drug discovery has focused almost exclusively on efficacy and selectivity against the biological target. As a result, nearly half of drug candidates fail at phase II and phase III clinical trials because of the undesirable drug pharmacokinetics properties, including absorption, distribution, metabolism, excretion and toxicity (ADMET). The pressure to control the escalating cost of new drug development has changed the paradigm since the mod-1990s. To reduce the attrition rate at more expensive later stages, in vitro evaluation of ADMET properties in the early phase of drug discovery has widely adopted. Faculty of Pharmaceutical science, ADTU 3

Many high-throughput in vitro ADMET property screening assays have been developed and applied successfully. Fueled by the ever-increasing computational power and significant advances of in silico modeling algorithms, numerous computational programs that aim at modeling ADMET properties have emerged. A comprehensive list of available commercial ADMET modeling software has been provided till date. Faculty of Pharmaceutical science, ADTU 4

Modeling technique: 2 Approaches The quantitative approaches represented by pharmacophore modeling and flexible docking studies investigate the structural requirements for the interaction between drugs and the targets that are involved in ADMET processes. These are especially useful when there is an accumulation of knowledge against certain target. For example, a set of drugs known to be transported by a transporter would enable a pharmacophore study to elucidate the minimum required structural features for transport. Three widely used automated pharmacophore perception tools are DISCO ( DIStance COmparisons ), GASP (Genetic Algorithm Similarity Program) and Catalyst/HIPHOP. Faculty of Pharmaceutical science, ADTU 5

The qualitative approaches represented by quantitative structure-activity relationship (QSAR) and quantitative structure-property relationship (QSPR) studies utilize multivariate analysis to correlate molecular descriptors with ADMET-related properties. A diverse range of molecular descriptors can be calculated based on the drug structure. Some of these descriptors can be calculated based on drug structure. It is essential to select the right mathematical tool for most effective ADMET modeling. Sometimes it is necessary to apply multiple statistical methods and compare the results to identify the best approach. Faculty of Pharmaceutical science, ADTU 6

Faculty of Pharmaceutical science, ADTU 7 In silico modeling target of drug disposition

Drug Absorption Because of its convenience and good patient compliance, oral administration is the most preferred drug delivery form. As a result, much of the attention of in silico approaches is focused on modeling drug oral absorption, which mainly occurs in the human intestine. In general, drug bioavailability and absorption is the result of the interplay between drug solubility and intestinal permeability. Faculty of Pharmaceutical science, ADTU 8

a ) Solubility A drug generally must dissolve before it can be absorbed from the intestinal lumen. By measuring a drug’s logP value (log of partition coefficient of compound between water and n - octanol ) and its melting point, one could indirectly estimate solubility using “general solubility equation”. To predict the solubility of compound even before synthesizing it, in silico modeling can be implemented . There are mainly two approaches to model solubility. One is based on the underlying physiological processes, and the other is an empirical approach. The dissolution process involves the breaking up of solute from its crystal lattice and the association of the solute with solvent molecules. Empirical approaches, represented by QSPR, utilize multivariate analysis to identify correlations between molecular descriptors and solubility. Faculty of Pharmaceutical science, ADTU 9

b) Intestinal Permeation Intestinal permeation describes the ability of drugs to cross the intestinal mucosa separating the gut lumen from the portal circulation. It is an essential process for drugs to pass the intestinal membrane before entering the systemic circulation to reach their target site of action. The process involves both passive diffusion and active transport. It is a complex process that is difficult to predict solely based on molecular mechanism. As a result, most current models aim to simulate in vitro membrane permeation of Caco-2, MDCK or PAMPA, which have been a useful indicator of in vivo drug absorption. Faculty of Pharmaceutical science, ADTU 10

Drug Distribution Distribution is an important aspect of drug’s pharmacokinetic profile. The structural and physiochemical properties of a drug determine the extent of distribution, which is mainly reflected by three parameters: volume of distribution ( Vd ), plasma-protein binding (PPB) and blood-brain barrier (BBB) permeability. Faculty of Pharmaceutical science, ADTU 11

Volume of Distribution ( Vd ) Vd is a measure of relative partitioning of drug between plasma and tissue , an important proportional constant that, when combined a drug is a major determinant of how often the drug should be administered. However , because of the scarcity of in vivo data and complexity of the underlying processes, computational models that are capable of prediction Vd based solely on computed descriptors are still under development. Faculty of Pharmaceutical science, ADTU 12

Plasma Protein Binding (PBP) Drugs binding to a variety of plasma proteins such as serum albumin, as unbound drug primarily contributes to pharmacological efficacy. The effect of PPB is an important consideration when evaluating the effective (unbound) drug plasma concentration. The models proposed to predict PBB should not rely on the binding data of only one protein when predicting plasma protein binding because it is a composite parameter reflecting interactions with multiple protein. Faculty of Pharmaceutical science, ADTU 13

Blood-Brain Barrier (BBB) The BBB maintains the restricted extracellular environment in the central nerve system. The evaluation of drug penetration through the BBB is an integral part of drug discovery and development process. Again , because of the few experimental data derived from inconsistent protocols, most BBB permeation prediction models are of limited practical use despite intensive efforts. Most approaches model log blood/brain ( logBB ), which is a measurement of the drug partitioning between blood and brain tissue. The measurement is an indirect implication of BBB permeability, which does not discriminate between free and plasma protein-bound solute. Faculty of Pharmaceutical science, ADTU 14

Drug Excretion The excretion or clearance of a drug is quantified by plasma clearance , which is defined as plasma volume that has been cleared completely free of drug per unit of time. Together with Vd , it can assist in the calculation of drug half-life, thus determining the dosage regimen. Hepatic and renal clearances are the two main components of plasma clearance. No model has been reported that is capable of predicting plasma clearance solely from computed drug structures. Current modeling efforts are mainly focused on estimating in vivo clearance from in vitro data. Just like other pharmacokinetic aspects, the hepatic and renal clearance process is also complicated by presence of active transporters. Faculty of Pharmaceutical science, ADTU 15

Active Transporters Transporters are an integral part of any ADMET modeling program because of their presence on barrier membranes and the substantial overlap between their substrates and many drugs. Unfortunately , because of our limited understanding of transporters , most prediction programs do not have a mechanism to incorporate the effect of active transport. However , interest in these transporters has resulted in a relatively large amount of in vitro data, which in turn have enabled the generation of pharmacophore and QSAR models for many of them. These models have assisted in the understanding of the complex effects of transporters on drug disposition, including absorption, distribution and excretion. Faculty of Pharmaceutical science, ADTU 16

Faculty of Pharmaceutical science, ADTU 17 Fig: Intestinal drugs transporters

Current Challenges and Future Direction The major recent advancement in ADMET modeling is in elucidating the role and successful modeling of various transporters. Incorporation of the influence of these transporters in the current models is an ongoing task in ADMET modeling. Some commercial programs have already implemented the capability of modeling active transport, such as recent version of GastroPlus (Simulation Plus, Lancaster,CA ), PK-Slim (Bayer Technology Services, Germany) and ADME/ Tox WEB ( Pharma Algorithms, Toronto, Canada). In the latter software, compounds are first screened against pharmacophore models of different active transporters. The compound that fits these models is removed for further predictions, which is based solely on physiochemical properties. Faculty of Pharmaceutical science, ADTU 18

Not all pharmaceutical companies can afford the resources to generate their own in-house modeling programs, so the commercially available in silico modeling suites have become an attractive option. Some modeling programs such as Algorithm Builder ( Pharma Algorithms, Toronto, Canada) are offering flexibility for costumers to generate their in-house models with their own training set and the statistical algorithm of their choice. These trends will accelerate the shift of model building from computational scientists to experimental scientists. Faculty of Pharmaceutical science, ADTU 19

References: Ekins S, “ Computer Applications in Pharmaceutical Research and Development ”, (2006) John Wiley and Sons Inc., chapter 20, pp495-508 Ekins S, Nikolsky Y and Nikolskaya T. Techniques: Application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci 2005;26;202-9 https:// hemonc.mhmedical.com/content.aspx?bookid=1810&sectionid=124489864 (accessed in 13 th May, 2018 ) Faculty of Pharmaceutical science, ADTU 20

Faculty of Pharmaceutical science, ADTU 21